AMA urges HHS to rescind new peptide compounding policy
The American Medical Association is urging HHS to rescind its policy allowing pharmacies to compound certain unapproved peptides, saying the “rushed” decision could expose patients to unsafe and unproven substances. The policy covers six peptides, BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon, none of which has FDA approval. The AMA said making them more widely […] The post AMA urges HHS to rescind new peptide compounding policy appeared first on Becker's Hospital Review | Healthc...
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.